Arana completes Phase II
Monday, 09 March, 2009
Arana Therapeutics, currently the subject of a takeover bid by US company Cephalon, has completed its Phase II trial of lead candidate ART621 in psoriasis.
The trial met the primary endpoints of tolerability and safety. Secondary findings included evidence of anti-tumour necrosis factor activity, a reduction in severity in some patients and no antibody responses against the drug, suggesting the drug has low immunogenicity, the company said.
ART621 is a human domain-based antibody directed against TNF. It is currently in two Phase II trials for rheumatoid arthritis in combination with methotrexate.
The study was conducted at the Nucleus Network in Melbourne and CMAX in Adelaide.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
